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Abstract
Exercise during cancer treatment improves cancer- related fatigue (CRF), but the im-
portance of exercise intensity for CRF is unclear. We compared the effects of high- 
vs low- to- moderate- intensity exercise with or without additional behavior change 
support (BCS) on CRF in patients undergoing (neo- )adjuvant cancer treatment. This 
was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials 
NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), 
prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo- )adjuvant treatment 
were randomized to high intensity (n = 144), low- to- moderate intensity (n = 144), 
high intensity with BCS (n = 144) or low- to- moderate intensity with BCS (n = 145). 
The 6- month exercise intervention included supervised resistance training and 
   | 1145DEMMELMAIER Et AL.
1 |  INTRODUCTION
Cancer survival rates have improved due to earlier detec-
tion and advances in treatment.1 However, cancer survi-
vors report long- term challenges, such as cancer- related 
fatigue (CRF), physical deconditioning, and decreased 
health- related quality of life (HRQoL).2 CRF is defined as 
a distressing, persistent sense of physical, emotional, and/
or cognitive tiredness or exhaustion that is not proportional 
to recent activity and interferes with usual functioning.3 
Prevalence of moderate- to- severe CRF during treatment 
is 30%- 60%,3 and clinically important CRF has been re-
ported in one- third of patients up to 6 years after treatment.4 
Symptom clusters of co- occurring CRF, pain and psycho-
logical distress may be persistent5 and are associated with 
lower HRQoL.6 The etiology of CRF is multifactorial, and 
treatment- induced activation of pro- inflammatory cyto-
kines may be one trigger.3
Exercise during and after treatment is effective in counter-
acting CRF,7 possibly by lowering the inflammatory activity 
and/or by increasing physical fitness.8 Exercise also improves 
HRQoL,9 may increase chemotherapy completion rates,10,11 
and reduce the risk of cancer mortality.12 International guide-
lines13 recommend 3 sessions of at least moderate- intensity 
endurance training and/or 2 sessions of at least moderate- 
intensity resistance training each week to counteract CRF. 
However, the evidence- base regarding the ideal “exercise pre-
scription” in terms of exercise frequency, intensity, duration, 
and type for cancer survivors is insufficient.13 While low- to- 
moderate intensity may be preferred by most patients,14 one 
study found that moderate- to- high- intensity exercise during 
cancer treatment was beneficial for physical fatigue com-
pared to low- intensity exercise.10 However, exercise volume 
was not controlled for, so the importance of intensity per se 
could not be determined. Second- generation studies compar-
ing different exercise intensities in relation to side effects, 
such as CRF, are therefore needed.13
Many patients find it difficult to perform physical ac-
tivity during oncological treatment, and they are on aver-
age less physically active than the general population.15 In 
exercise interventions, adherence rates have been reported 
between 23%16 and 84%, 17 depending on the characteris-
tics of the sample, the intervention and the method used to 
calculate adherence. Interview studies indicate a need for 
individualized support to overcome barriers such as side 
effects and external demands.18 Behavior change support 
(BCS) can be used to overcome such barriers. Systematic 
reviews and meta- analysis have identified behavior change 
strategies associated with high adherence and larger effect 
sizes in interventions designed to increase physical activity 
among cancer survivors. Examples of such techniques are 
self- monitoring,19 goal- setting,20 graded tasks,20,21 social 
support22 and supervision.20,22 However, if BCS can influ-
ence health outcomes through increased intervention, adher-
ence is unclear due to limitations in study methodology and 
reporting.20,23
The primary aim of this second- generation study was to 
determine the effects of high- vs low- to- moderate- intensity ex-
ercise with or without additional BCS on CRF (primary end-
point) in patients undergoing (neo- )adjuvant cancer treatment. 
home- based endurance training. CRF was assessed by Multidimensional Fatigue 
Inventory (MFI, five subscales score range 4- 20), and Functional Assessment of 
Chronic Illness Therapy- Fatigue scale (FACIT- F, score range 0- 52). Multiple linear 
regression for main factorial effects was performed according to intention- to- treat, 
with post- intervention CRF as primary endpoint. Overall, 577 participants (mean age 
58.7 years) were randomized. Participants randomized to high- vs low- to- moderate- 
intensity exercise had lower physical fatigue (MFI Physical Fatigue subscale; mean 
difference −1.05 [95% CI: −1.85, −0.25]), but the difference was not clinically im-
portant (ie <2). We found no differences in other CRF dimensions and no effect of 
additional BCS. There were few minor adverse events. For CRF, patients undergoing 
(neo- )adjuvant treatment for breast, prostate or colorectal cancer can safely exercise 
at high- or low- to- moderate intensity, according to their own preferences. Additional 
BCS does not provide extra benefit for CRF in supervised, well- controlled exercise 
interventions.
K E Y W O R D S
behavior change, cancer- related fatigue, endurance training, oncology, resistance training
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Secondary aims were to determine the effects on HRQoL, anx-
iety/depression, function in daily life, cardiorespiratory fitness, 
muscle strength, level of physical activity, sedentary time, 
sleep, and treatment completion rates.
2 |  METHODS
2.1 | Design
The Physical training and Cancer (Phys- Can) study was a 
Swedish three- center, 2  ×  2 factorial design randomized 
controlled trial (Figure 1), previously described in depth.24 
Briefly, participants were randomized to high- or low- to- 
moderate- intensity exercise, with or without additional 
BCS (ClinicalTrials.gov NCT02473003). The Swedish 
Ethical Review Authority approved the study (Dnr 
2014/249).
Coaches (qualified and experienced physiotherapists, 
n = 13 or personal trainers, n = 2) were assigned to lead an 
intervention group based on logistics, scheduling and their 
additional competence in BCS. Each coach supervised 
participants in both exercise intensity groups. However, 
coaches who provided additional BCS supervised only 
those groups.
There were no major changes to the study after the trial 
commenced.
2.2 | Participants
Participants were recruited from Uppsala, Lund and Linköping 
University hospitals from March 2015 to April 2018. Eligible 
participants, assessed by an oncologist, were > 18 years, lit-
erate in Swedish and recently diagnosed with curable breast 
(women only), prostate or colorectal cancer, scheduled to 
begin (neo- )adjuvant chemotherapy, radiotherapy, and/or 
endocrine therapy. The chemotherapy treatment period was 
typically 4 months for breast cancer and 6 months for colo-
rectal cancer. Radiotherapy treatment was typically 2 months 
for prostate cancer and 3 weeks for breast cancer. Endocrine 
therapy was scheduled for 2.5- 10 years and antibody treat-
ment for 6- 12 months.
Exclusion criteria were stage IIIb- IV breast cancer, inabil-
ity to perform basic activities of daily living, cognitive disor-
ders, severe psychiatric disease, or other disabling conditions 
that might contraindicate high- intensity exercise (eg, severe 
heart failure, severe chronic obstructive pulmonary disease, 
or orthopedic conditions), treatment for an additional ongo-
ing malignant disease, BMI < 18.5 kg/m2 or pregnancy. A 
research nurse/assistant provided oral and written informa-
tion to eligible participants prior to start of treatment. Those 
willing to participate gave written informed consent before 
baseline data collection.
2.3 | Interventions
The 6- month intervention was initiated at start of the (neo- )
adjuvant cancer treatment as described in Table 2. The su-
pervised, group- based resistance training at public gyms 
was performed twice/week (Figure  S1). The home- based 
endurance training at high intensity consisted of interval 
training, performed twice/week, while low- to- moderate- 
intensity endurance training consisted of 150  weekly 
minutes of walking or biking. Additional BCS, such as 
goal- setting, planning, and self- monitoring, was delivered 
face- to- face jointly with the resistance training sessions. 
Patients with breast cancer, scheduled for neo- adjuvant 
chemotherapy, exercised during the four months pre- 
surgery only. Standardized delivery of both exercise and 
additional BCS was assessed and enhanced as described 
in Table 2.
The intervention was developed by researchers with ex-
pertise in exercise physiology, BCS, and physiotherapy in 
collaboration with clinicians (oncologists and physiothera-
pists) and patient representatives.
2.4 | Outcomes and data management
Follow- up data collection was completed in November 
2018. CRF was assessed with the Multidimensional 
Fatigue Inventory (MFI),25 measuring General, Physical 
and Mental Fatigue, Reduced Motivation and Reduced 
Activity, each subscale range 4- 20. Based on previous re-
search,10 the Physical Fatigue subscale was used for power 
calculation.
CRF was also assessed with Functional Assessment of 
Chronic Illness Therapy— Fatigue (FACIT- F) scale,26 a fre-
quently used single- scale questionnaire with range 0- 52.
All outcomes were assessed with well- established and 
validated methods completed at home, at baseline (before 
randomization) and immediately post- intervention. HRQoL 
was assessed with European Organisation for Research and 
Treatment of Cancer (EORTC) QLQ- C30,27 anxiety and 
depression with Hospital Anxiety and Depression Scale 
(HADS)28 and functioning in daily life with World Health 
Organization Disability Assessment Schedule (WHODAS) 
2.0 Work and Social Participation subscales.29 Muscle 
strength was assessed with 1 repetition maximum (RM) test 
of upper and lower extremities. Chemotherapy completion 
rate was reported as relative dose intensity based on data from 
medical records.30 For details about assessment methods, 
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Table  S1. Composite scores for questionnaires were calcu-
lated according to published instructions.
Physical activity was measured using SenseWear 
Armband mini (BodyMedia Inc, Pittsburgh, PA, USA) at 
baseline and post- intervention, as described in Table  S1. 
A minimum of 80% wear time for four out of seven days 
was required for data to be included. Mean sedentary time 
per 24  hours was considered to be time spent at 0- 1.5 
F I G U R E  1  CONSORT diagram of flow of participants through the Phys- Can study. Numbers with (in)complete baseline and follow- up data 
are based on cancer- related fatigue (MFI physical fatigue subscale), exact numbers for other outcomes vary (Table 1). Follow- up refers to data 
collected at the post- intervention. HI, high- intensity exercise, LMI, low- to- moderate- intensity exercise, BCS, additional behavior change support
Assessed for eligibility (n=2600)
Ineligible (n=549)
Did not understand Swedish (n=48)
Could not perform basic activity (n=43)
Comorbid condition (n=410)
Other reason/reason unknown (n=48)
Included in study (n=600, 29% of eligible participants)
Declined participation (n=1451)
Feeling too bad (n=69)
Too far to travel (n=425)
Does not want to state reason (n=106)
Administrative error (n=109)
Other reason/reason unknown (n=742)
Randomised (n=577)
Withdrew before randomisation (n=23)
Feeling too bad (n=4)
Too far to travel (n=1)
Too busy/intervention does not fit with schedule (n=5)
Other reason/reason unknown (n=13)
HI with BCS (n=144) HI without BCS (n=144) LMI with BCS (n=145) LMI without BCS (n=144)
Incomplete data (n=35)
















Withdrew before follow-up 
(n=21)
Missing follow-up (n=12)
Complete baseline and 
follow-up data (n=109)
Complete baseline and 
follow-up data (n=106)
Complete baseline and 
follow-up data (n=102)
Complete baseline and 
follow-up data (n=110)
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METs according to SenseWear algorithms and mean time 
in moderate- to- vigorous intensity physical activity (MPVA) 
per 24 hours was considered to be that of at least 3 METs 
according to SenseWear algorithms.31
Cardiorespiratory fitness was independently assessed 
in dedicated exercise laboratories using maximal oxygen 
uptake (VO2max) tests with gas exchange measurement, 
walking/running to exhaustion using a modified Balke pro-
tocol.32 Tests were accepted if two out of three criteria were 
fulfilled: (a) tester judged the test as maximal, (b) Borg 
RPE33 rating ≥ 17 and (c) respiratory exchange ratio (RER) 
≥1.1.34
Exercise adherence was recorded as absolute numbers of 
performed sessions and calculated as % volume. Exercise 
volume (frequency, intensity, and time) was calculated as 
performed exercise divided by prescribed (maximum possi-
ble) exercise, in accordance with previous research.35 This 
calculation resulted in one proportion (0%- 100%) for resis-
tance training and one proportion (0%- 100%) for endurance 
training for each participant. These proportions were pooled 
to mean adherence per exercise component and intervention 
group. For details, Table 2 under the heading “Calculation of 
adherence.”
2.5 | Sample size
An a- priori power calculation showed that 600 participants 
(150 per trial arm) were required to detect main factorial 
effects of exercise intensity and BCS on the MFI Physical 
Fatigue subscale,36 with a minimum clinically important dif-
ference of 2 points (SD 5) post- intervention and 80% power 
at alpha level 0.05. This calculation allowed for missing data 
and drop- out from the study.24
2.6 | Randomization
The random allocation sequence with a ratio of 1:1:1:1 was 
computer generated and thus concealed from all research 
staff. Within each stratum (3 centers and 3 diagnoses) rand-
omization was carried out following a permuted block design 
with 8 participants per block. Once baseline data collection 
was finalized, each participant was automatically assigned to 
an intervention group using a web- portal.
2.7 | Blinding
Blinding of coaches and participants to the intervention 
group was not feasible. However, coaches and participants 
were informed that there was limited evidence for which in-
tensity would be more beneficial for CRF.
2.8 | Statistical methods
Differences in baseline characteristics between those in-
cluded in analysis and those who withdrew were examined 
using t tests for continuous variables and chi- squared tests for 
categorical variables.
Multiple linear regression was used to simultaneously 
estimate the main effect for exercise intensity (high- vs 
low- to- moderate intensity) and BCS (with vs without), and 
their interaction (intensity  ×  BCS) on each outcome post- 
intervention. Results are presented as adjusted mean differ-
ence with 95% Confidence Intervals (95%CI). Analyses were 
conducted according to intention- to- treat. Models included 
baseline measures of the outcome to increase precision and 
were adjusted for center and cancer diagnosis.
Missing data were accounted for using multiple impu-
tations by chained equations. Auxiliary variables used to 
inform imputed values were age, education level, center, di-
agnosis, chemotherapy treatment, baseline values of outcome 
measure, and intervention group. Where missing data at 
baseline were > 10%, baseline data for that outcome were not 
included as an auxiliary variable or as a variable in the main 
models, as baseline data were deemed not to add additional 
precision for these outcomes.37,38
Differences between intervention groups in adherence to re-
sistance and endurance training volume were examined using 
one- way ANOVA. Among participants in the low- to- moderate- 
intensity groups minutes of exercise above the prescribed in-
tensity (ie, >60% of heart rate reserve) were compared between 
those who did and did not receive additional BCS using a t test.
A supplementary analysis based on complete cases was 
performed. In addition, each cancer diagnosis was examined 
separately; these models were adjusted for center and base-
line measures of the outcome variable.
Analyses were carried out in Stata version 15.0.
2.9 | Patient and public involvement
Patient representatives, one from each diagnosis group, were 
included in the project group. They were involved in the de-
sign of the study, the content of the intervention, informa-
tional material, and provided feedback on the burden of the 
intervention. They will help disseminate the results within 
their respective patient organization.
3 |  RESULTS
3.1 | Recruitment
Six hundred (29%) of 2051 eligible patients agreed to par-
ticipate (Figure 1). Participation rate per diagnosis was 30% 
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T A B L E  2  Description of resistance training, endurance training and additional behavior change support (BCS) components of the 
intervention, according to 2017 CONSORT checklist for reporting randomized trials assessing non- pharmacological treatment
Resistance training Endurance training Additional BCS
Content High intensity: 3 × 6 RM (2 min 
rest between sets) once a week. 
Last set until failure.
3 × 10 RM (1 min rest between 
sets) once a week. Last set until 
failure.
Low- to- moderate intensity: 3 × 12 
repetitions at 50% of 6 RM (2 min 
between sets) once a week.
3 × 20 repetitions at 50% of 10 RM 
(1 min rest between sets) once a 
week.
Two sessions per week.
High intensity: Twice- weekly interval 
sessions. Two minutes of exercise (running, 
cycling, walking up- hill) at 80%- 90% HRR 
followed by two minutes of active rest. 
Progression from 5 intervals, adding intervals 
over time until max 10 intervals. Warm- up 
and cool- down for 5- 10 min, respectively.
Low- to- moderate intensity: 150 weekly 
minutes of endurance activity (walking, 
cycling) in bouts of minimum 10 min at 40%- 
50% of HRR.
HRR was determined for each participant 
based on a VO2max test performed before the 
intervention.
Coaches guided participants in using 
strategies to facilitate adherence to 
the exercise, focusing mainly on 
the home- based endurance training: 
Goal- setting
Short- term action planning
Self- monitoring
Review of goal- setting
Behavioral analysis
Long- term coping planning
Setting Supervised at public gyms in groups 
of typically 5- 10 participants. 
Separate groups for each of the 
four conditions.
Home- based. Face- to- face concurrent with 
resistance training at the gym. Only 
self- monitoring was home- based 
and performed by the participants 
after endurance training. Long- term 
coping planning was performed at 
the end of the exercise period.
Tailoring Individually adapted weights based 
on repeated testing of 6 and 10 
RM in all exercises. Weights 
were lowered temporarily for 
participants struggling with severe 
side effects, and then successively 
increased. Exercises that caused 
pain were substituted with other 
exercises activating the same 
muscle groups.
Individually adapted intensity based on 
VO2max tests and heart rate monitors.
Type of activity according to individual 
preferences, eg walking, bicycling, running.
Adapted to the participants’ needs; 
fewer/short reviews if goals 
were easily reached every week. 
Goal- setting and action planning 
specifying when, where and how 
to train. Based on interviews about 
previous exercise habits. Self- 
monitoring by extended logbooks 
with facilitators and barriers in 
specific situations. Review and 
adjustment of goal- setting to be 
important and realistic to the 
participant. Analysis by identifying 
determinants of training, based on 
logbooks and discussions.
Long- term coping planning 
according to participants’ 
preferences about maintained 
physical activity/exercise.
Standardization Familiarization period of 6 wk. 
Six exercises; 3 for the upper 
extremities and three for the 
lower extremities. Four additional 
exercises for the trunk and 
pelvic floor were advised but not 
controlled (Figure S1). Progression 
based on testing of 6 and 10 RM 
every 4- 6 wk.
Familiarization period of three weeks. All 
participants wore heart rate monitors and 
recorded their exertion according to the Borg 
RPE [27] in exercise logbooks.
Weekly reviews during the first 
month and then typically every 
4- 6 wk, included in week- to- week 
checklists. Printed sheets for 
coaches to align the procedures 
for goal- setting, action planning, 
review of goal- setting, analysis, 
and long- term coping planning. 
Electronic or printed extended 
logbooks for participants’ 
self- monitoring.
(Continues)
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Three- day course for coaches on 
supervising participants’ exercise 
according to a detailed intervention 
protocol. Repeated on- site visits 
and project group meetings with 
research staff on five occasions. 
Twice- monthly teleconferences 
with coaches from each site to 
discuss and align the delivery of 
the intervention. Week- by- week 
checklist for each participant, 
corresponding to the intervention 
protocol, was used by coaches.
See left. BCS coaches had three additional 
course days with theory and 
practice on BCS and a detailed 
protocol. Repeated on- site visits by 
research staff and project meetings 
on five occasions. Audio recordings 
of reviews were used twice to 
assess the coaches’ use of BCS and 
feedback was provided to them by 
research staff.
Non- BCS coaches had a protocol 
specifying what they were not 
allowed to do. These restrictions 
and any problems with adhering to 
them were followed up repeatedly at 





Week- by- week checklist for each 
participant with attendance, 6 
and 10 RM test results and notes 
about deviations from the protocol. 
Printed logbooks where target 
weights were recorded by the 
coaches. The coaches checked 
adherence to the protocol and 
gave feedback at each session. 
If participants did not attend a 
resistance training session, they 
were contacted by telephone and 
encouraged to attend the next 
session.
Files from heart rate monitors were reviewed 
by coaches together with the participants. All 
participants completed standardized logbooks 
for endurance training, either electronically 
or by paper. Pulse files and logbooks were 
checked for intensity and overall adherence 
and feedback was provided.
For self- monitoring, the extended 
logbooks were checked regularly 
by the coaches and the participants 
were encouraged to use them. Goal- 
setting reviews and analysis were 
performed weekly during the first 
month of the exercise period and 
then typically every 4- 6 wk. Long- 
term coping plans were written; one 
copy for the participant and one for 
the coach to follow- up. Telephone 
follow- up by coach at 3 and 9 after 
end of the exercise period.
Calculation of 
adherence
Performed training divided by 
maximum possible training using 
logbook data.
Performed training was performed 
weight × performed number of 
repetitions, summed across all 
exercises and training sessions. 
Maximum possible training was 
weight × number of repetitions 
according to the protocol summed 
across all exercises and maximum 
possible training sessions.
Performed training divided by maximum 
possible training using a combination of 
logbook and pulse file data.
High intensity: Performed training was 
number of intervals × interval duration 
summed across all training sessions with an 
average intensity of minimum 90% of the 
80% lower HRR limit. This adjustment was 
made to take into account biking sessions; 
lower HR despite similar exertion level as 
running. Maximum possible training was 
number of intervals × interval duration 
(2 min) × 2 × number of weeks of training 
according to the protocol.
Low- to- moderate intensity: Performed training 
was minutes of activity of an intensity of 
40%- 60% of HRR. Adjustment of upper 
limit was made as general heart rate increase 
is common during chemotherapy/cortisol 
treatment. Maximum possible training was 
150 × number of weeks of training according 
to the protocol. In addition, calculation 
of minutes of activity at > 60%, enabling 
adjustment for high intensity.
Performed number of sessions 
including reviews and action 
planning divided by the maximum 
possible number of sessions 
according to the protocol (n = 9).
Abbreviations: HRR, Heart rate reserve; RM, Repetition maximum; RPE, Rating of perceived exertion; VO2max, Maximum oxygen respiratory uptake.
T A B L E  2  (Continued)
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for breast cancer, 22% for prostate cancer, and 20% for colo-
rectal cancer. Participants, compared to those who declined 
participation, were younger (mean age 58.7 vs 63.6 years, P- 
value <  .001) and less likely to have prostate or colorectal 
cancer than breast cancer (OR [95%CI]; colorectal cancer, 
0.58 [0.36- 0.92]; prostate cancer, 0.65 [0.51- 0.83]). Twenty- 
three participants withdrew from the study before randomiza-
tion. In total, 577 participants were randomized.
3.2 | Baseline characteristics of randomized 
participants
Breast cancer was the most common diagnosis (n  =  457), 
followed by prostate cancer (n = 97) and colorectal cancer 
(n = 23). Most participants with breast (84.5%) or prostate 
(66.7%) cancer received combinations of (neo- )adjuvant 
treatments. Among these participants, the most common 
combinations were chemotherapy with radiotherapy and en-
docrine treatment for breast cancer (30.4%) and combined 
neo- adjuvant and adjuvant endocrine treatment for prostate 
cancer (51.5%). All participants with prostate cancer also 
received curative radiotherapy. All participants with colo-
rectal cancer received adjuvant chemotherapy (Table  3). 
Time between diagnosis and randomization was median 61 
(interquartile range 44- 86) days, and there was a median 
of 7 (interquartile range 5- 11) days between randomization 
and starting the intervention. Sociodemographic, disease, 
and treatment characteristics, as well as physical fitness and 
physical activity levels, were similar across all four interven-
tion groups (Tables 3 and S2).
3.3 | Missing data
Overall, 89 randomized participants withdrew from the study 
before the follow- up assessment. The reasons for withdrawal 
were too far to travel/lack of time (n = 36), illness/side ef-
fects of treatment (n = 25) and lack of motivation/disliked 
training (n  =  10), with similar distribution between inter-
vention groups. Eighteen participants did not provide a rea-
son. Missing baseline data on outcomes ranged from n = 20 
(FACIT- F) to n = 113 (VO2max) (Table S3). Missing data 
were not associated with intervention group, age, living situa-
tion, education, weight status, and general, physical or mental 
fatigue. However, individuals who were not included in the 
analysis of the main outcome had slightly lower cardiorespi-
ratory fitness (VO2max mean [SD]: 29.2 [7.5] vs 30.8 [7.0] 
mL/kg/min P- value = .043) and HRQoL (EORTC QLQ- C30 
summary score mean [SD]: 80.6 [13.7] vs 83.7 [12.0] P- 
value = .013) at baseline compared to those included.
3.4 | Primary outcome
Participants randomized to exercise at high compared with 
low- to- moderate intensity had lower MFI physical fatigue 
(adjusted mean difference −1.05 [95% CI, −1.85 to −0.25]) 
(Table 4), while there were no differences for the other MFI 
subscales or for FACIT- F. Moreover, there were no main ef-
fects for additional BCS and no exercise intensity- BCS inter-
actions for any CRF measures.
3.5 | Secondary outcomes
There were no main effects of exercise intensity or ad-
ditional BCS on HRQoL based on the EORTC QLQ C- 30 
Summary Score (Table 4). However, there was an interaction 
effect indicating that in the groups receiving additional BCS, 
high- intensity exercise was associated with a lower HRQoL 
compared to low- to- moderate intensity, while in the groups 
not receiving BCS high- intensity exercise was associated 
with higher HRQoL compared to low- to- moderate intensity 
(Table 4 and Table S4).
Participants randomized to exercise at high- vs low- to- 
moderate intensity had better cardiorespiratory fitness (ad-
justed mean difference 1.61 [95% CI 0.19- 3.04] mL/kg/
min) and greater leg strength (adjusted mean difference 3.98 
[95% CI 0.58- 7.38] kg) (Table  4). There were no main or 
interaction effects of additional BCS for these outcomes. An 
exercise intensity- BCS interaction was observed for MVPA 
(Table 4).
There were no main or interaction effects of the interven-
tion on anxiety, depression, functioning in daily life, sleep, 
sedentary behavior, chemotherapy completion rates, or rela-
tive dose intensity (Table 4).
For chemotherapy completion rates, 118 participants 
(39.6%) out of 298 had dose reduction or treatment discontin-
uation. Mean relative dose intensity was 90.2% in high inten-
sity with BCS, 92.6% in high intensity without BCS, 93.6% 
in low- to- moderate intensity with BCS, and 92.9% in low- to- 
moderate intensity without BCS (Table S5). There were no 
adjustments of radiotherapy dose for any participant.
3.6 | Supplementary analyses
The results from the complete case analysis were similar to 
the main results, that is, the MFI Physical Fatigue scale dif-
fered significantly, in favor of the high- intensity exercise 
groups (Table  S3). However, in contrast to the intention- 
to- treat analysis, VO2max did not differ between groups in 
the complete cases analysis. Diagnosis- specific analyses 
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T A B L E  3  Sociodemographic, disease and planned treatment data at baseline by intervention group for randomized participants. Data are mean 
(SD) or number (%). N vary due to missing data, % is of those with data available
HI with BCS (n = 144)
HI without BCS 
(n = 144)




Age, y 59.3 (13.0) 58.1 (11.4) 58.0 (11.6) 59.6 (11.8)
Sex
Female 115 (79.9) 116 (80.6) 118 (81.4) 116 (80.6)
Living situation
Living with partner 112 (80.0) 114 (83.2) 117 (84.2) 109 (79.6)
Education
University 79 (56.0) 84 (60.9) 92 (65.7) 81 (58.3)
Smoking or using snuff
Never 72 (57.6) 70 (54.3) 76 (59.8) 70 (53.4)
Previous/less than daily 44 (35.2) 53 (41.1) 47 (37.0) 47 (35.9)
Daily 9 (7.2) 6 (4.7) 4 (3.1) 14 (10.7)
Weight status
Normal weight, BMI 
18- 24.9 kg/m2
60 (45.5) 72 (52.2) 66 (49.3) 69 (50.0)
Pre- obese, BMI 25- 29.9 kg/m2 44 (33.3) 46 (33.3) 54 (40.3) 44 (31.9)
Obese, BMI > 29.9 kg/m2 28 (21.2) 20 (14.5) 14 (10.4) 25 (18.1)
Comorbidities
Yes 79 (57.7) 78 (58.6) 77 (55.4) 93 (66.4)
Current exercise habitsa 
Endurance training 
since > 6 mo
41 (35) 49 (40) 51 (42) 38 (30)
Resistance training 
since > 6 mo
27 (23) 25 (21) 22 (19) 14 (12)
Self- reported importance ofb 
HI endurance training 56 (32) 58 (34) 60 (31) 54 (34)
LMI endurance training 77 (28) 76 (27) 79 (26) 79 (22)
Resistance training 68 (29) 71 (30) 72 (29) 70 (29)
Breast cancerc 113 115 116 113
T in situ- T1 69 (69.7) 63 (63.6) 56 (55.4) 69 (69.7)
T2- T3 30 (30.3) 35 (35.4) 45 (44.6) 30 (30.3)
N1 15 (15.2) 16 (16.2) 15 (14.9) 17(17.2)
Chemotherapyd 70 (67.3) 66 (61.1) 69 (64.5) 71 (67.0)
Adjuvant 60 (85.7) 52 (78.8) 58 (84.1) 61 (85.9)
Neo- adjuvant 10 (14.3) 14 (21.2) 11 (15.9) 10 (14.1)
Antibody treatment 20 (28.6) 19 (28.8) 17 (24.6) 23 (32.4)
Radiotherapye 84 (80.8) 88 (81.5) 85 (79.4) 92 (86.8)
Endocrine treatment 72 (69.2) 75 (69.4) 84 (78.5) 79 (74.5)
Prostate cancer 26 23 23 25
T1- T2 20 (76.9) 19 (82.6) 17 (73.9) 18 (72.0)
T3- T4 2 (7.7) 3 (13.0) 1 (4.3) 4 (16.0)
N1 1 (3.8) 0 3 (13.0) 1 (4.0)
Radiotherapyf 25 (100.0) 20 (100.0) 22 (100.0) 25 (100.0)
Endocrine treatment 13 (50) 13 (56.5) 10 (43.5) 15 (60)
(Continues)
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reflected the main results for all diagnostic groups (Tables S6 
and Tables S7) but were underpowered for participants with 
colorectal cancer and weaker for those with prostate cancer.
3.7 | Intervention adherence
Participants completed on average 50.4% of the prescribed 
resistance training volume, with no differences between 
intervention groups (P  =.438) (Figure  2). For attendance 
specifically, the absolute mean (SD) number of performed 
sessions during the intervention period was 25 (10). Reported 
per group, mean (SD) number of performed sessions was 23 
(10) for high intensity with BCS, 24 (9) for high intensity 
without BCS, 26 (10) for low- to- moderate intensity with 
BCS, and 26 (8) for low- to- moderate intensity without BCS.
Adherence to home- based endurance training volume 
differed between groups ( mean [SD] % was 38.8 (33.1) 
for high intensity with BCS, 41.6 (33.6) for high intensity 
without BCS, 57.7 (38.3) for low- to- moderate intensity with 
BCS, and 51.4 (38.7) for low- to- moderate intensity without 
BCS, P <.001) and pair- wise comparisons are presented in 
Figure 2. The absolute mean (SD) number of performed in-
terval sessions during the intervention period was 23 (17) 
for high intensity with BCS and 23 (16) for high intensity 
without BCS. The mean (SD) number of continuous train-
ing sessions (minimum 10- minute bouts) was 73 (66) for 
low- to- moderate intensity with BCS and 70 (61) for low- 
to- moderate intensity without BCS. Among participants in 
the low- to- moderate- intensity groups those who received 
additional BCS performed more minutes of exercise above 
the prescribed intensity (ie, >60% of heart rate reserve) than 
those who did not receive additional BCS (506 vs 326 min-
utes, P- value = .026).
3.8 | Adverse events due to intervention
Thirty- two minor adverse events in 30 participants (n  =  8 
high intensity with BCS, n = 12 high intensity without BCS, 
n  =  6 low- to- moderate with BCS, n  =  4 low- to- moderate 
without BCS) prevented them from completing the ongoing 
training session. These events included muscle strains, joint 
pain, and dizziness. In addition, three participants needed to 
attend hospital as a result of exercise; one injured a finger, 
and two fainted.
4 |  DISCUSSION
This was a large, second- generation RCT designed to exam-
ine the effects of exercise intensity per se on CRF and other 
health outcomes during cancer treatment. High- intensity re-
sistance and endurance exercise yielded significantly lower 
physical fatigue compared to low- to- moderate- intensity ex-
ercise in patients undergoing (neo- )adjuvant treatment, but 
the magnitude of effect did not reach the minimal clinically 
important difference of two points.36 Further, there were no 
differences between groups in other CRF dimensions. There 
were few minor adverse events, which indicates that exer-
cise is safe, even at high intensity, for these patient groups. 
Although there were small benefits of high- intensity exer-
cise for muscle strength and cardiorespiratory fitness, over-
all, patients undergoing (neo- )adjuvant treatment for breast, 
HI with BCS (n = 144)
HI without BCS 
(n = 144)




Colorectal cancerg 5 6 6 6
T2- T4 5 (100.0) 6 (100.0) 6 (100.0) 5 (100.0)
N1- N2 5 (100.0) 4 (66.7) 4 (66.7) 5 (100.0)
Chemotherapyh 5 (100.0) 6 (100.0) 6 (100.0) 5 (100.0)
Abbreviations: BCS, Additional behavior change support; BMI, body mass index; HI, High- intensity exercise; LMI, Low- to- moderate- intensity exercise; T, tumor size. 
N, lymph node status.
aExercise Stage Assessment Instrument categories 1- 5 with 1 = Pre- contemplation stage and 5 = Maintenance stage, physically active longer than 6 mo. 
bVisual analogue scale 0- 100 mm anchored at “Not at all important” and “Very important”. 
cOne participant in HI without BCS had stage T4d treated with curative intent. Two participants in LMI without BCS had N2 and one in LMI with BCS had N3. 
dChemotherapy was Epirubicine- based and/or Taxane- based. 
eBreast and/or axilla. 
fBrachy and/or external. 
gOne participant in HI with BCS had radically removed liver metastasis. One participant in HI with BCS and two in HI without BCS had pre- operative radiotherapy. 
hCapecitabine- Oxaliplatin or Capecitabine only. 
T A B L E  3  (Continued)
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T A B L E  4  Main effects of exercise intensity, additional behavior change support, and interaction post- intervention after multiple imputation by 
chained equations to account for missing data, presented as adjusted mean difference and 95% confidence intervals (n = 577)
Exercise intensity 
AMD (95%CI) BCS AMD (95%CI)
Interaction AMD 
(95%CI)
P- value for 
interaction effect
Primary outcome CRF
MFI General Fatigue −0.36 (−1.04 to 0.33) −0.20 (−0.91 to 0.51) 0.19 (−0.53 to 0.91) .608
MFI Physical Fatigue −1.05 (−1.85 to −0.25) −0.43 (−1.21 to 0.34) 0.26 (−0.55 to 1.08) .524
MFI Reduced Activity 0.22 (−0.49 to 0.92) −0.35 (−1.04 to 0.35) −0.05 (−0.76 to 0.67) .899
MFI Reduced Motivation 0.05 (−0.53 to 0.64) −0.27 (−0.83 to 0.30) 0.31 (−0.25 to 0.87) .276
MFI Mental Fatigue −0.26 (−0.94 to 0.42) −0.20 (−0.88 to 0.48) 0.36 (−0.32 to 1.04) .304
FACIT Fatigue subscale −0.43 (−1.87 to 1.01) −0.11 (−1.59 to 1.36) −0.63 (−2.09 to 0.84) .401
Secondary outcomes
EORTC QLQ- C30 Summary Score −0.64 (−2.42 to 1.15) −0.77 (−2.51 to 0.97) −2.83 (−4.61 to −1.05) .002
HADS Depression 0.03 (−0.45 to 0.50) −0.24 (−0.74 to 0.27) 0.17 (−0.32 to 0.66) .495
HADS Anxiety 0.16 (−0.39 to 0.71) 0.23 (−0.35 to 0.81) 0.51 (−0.06 to 1.08) .079
WHODAS Work subscalea 0.31 (−1.01 to 1.63) 0.42 (−0.86 to 1.71) 0.73 (−0.59 to 2.06) .277
WHODAS Social Participation 
subscale
0.12 (−0.68 to 0.91) 0.36 (−0.45 to 1.18) 0.51 (−0.28 to 1.30) .206
Average 1RM left & right leg, kgb 3.98 (0.58 to 7.38) 2.85 (−0.59 to 6.29) −0.66 (−3.86 to 2.55) .687
1RM chest press, kgb 0.41 (−1.62 to 2.44) 1.47 (−0.52 to 3.47) −1.40 (−3.41 to 0.61) .171
VO2max, mL/kg/min
b 1.61 (0.19 to 3.04) 0.76 (−0.68 to 2.20) −1.25 (−2.67 to 0.16) .082
Sleep, h/db 0.10 (−0.15 to 0.34) −0.03 (−0.27 to 0.22) −0.10 (−0.33 to 0.14) .422
Sedentary time, h/db −0.26 (−0.68 to 0.16) −0.13 (−0.54 to 0.28) 0.26 (−0.14 to 0.66) .204
MVPA, h/db 0.06 (−0.14 to 0.26) 0.07 (−0.13 to 0.26) −0.26 (−0.45 to −0.07) .008
Relative Dose Intensity, %c −1.54 (−4.46 to 1.39) −0.99 (−3.94 to 1.96) −1.99 (−4.93 to 0.95) .184
Abbreviations: 1RM, 1 repetition maximum; 95%CI, 95% confidence intervals; AMD, Adjusted mean difference; BCS, Additional behavior change support; CRF, 
Cancer- related fatigue; EORTC QLQ- C30, European Organisation for Research and Treatment of Cancer, Quality of life Questionnaire C30; FACIT, Functional 
Assessment of Chronic Illness Therapy; HADS, Hospital Anxiety and Depression scale; MFI, Multidimensional Fatigue Inventory; MVPA, moderate- to- vigorous 
intensity physical activity; VO2max, maximal volume of oxygen uptake; WHODAS, World Health Organization Disability Assessment Schedule.
aFor participants who reported working. 
bBaseline values not included in analysis due to missing data > 10%. 
cFor participants treated with chemotherapy. Linear regression analyses adjusted for hospital, cancer site, and baseline measure of outcome. Bold indicates 
P- value < .05. 
F I G U R E  2  Adherence to prescribed 
strength and endurance training volume, 
by training group. Bars represent mean 
adherence, error bars indicate 1 standard 
deviation from the mean. Participants who 
dropped out of the study were recorded 
as 0 adherence to any remaining training 
sessions. P- values reflect pair- wise 
comparisons across the four intervention 
groups using Tukey post hoc tests. All 
other pair- wise comparisons resulted 
in P- values > .05. HI, high- intensity 
exercise, LMI, low- to- moderate- intensity 





1156 |   DEMMELMAIER Et AL.
prostate, or colorectal cancer can be advised to exercise at 
either intensity, according to their own preferences. Finally, 
our results suggest that in a motivated and relatively healthy 
sample, additional BCS does not influence CRF.
In line with our results, van Waart et al demonstrated sta-
tistically lower physical fatigue after combined resistance 
and endurance exercise at moderate- to- vigorous intensity 
compared to low- intensity walking during adjuvant chemo-
therapy,10 but did not find a minimum clinically important 
difference between groups.36 However, van Waart et al did 
not control for exercise volume, which limited the possibili-
ties to draw conclusions about the effect of exercise intensity 
per se.
Kampshoff et al reported no between- group differences 
in CRF for high- vs low- to- moderate- intensity exercise after 
cancer treatment.39 An RCT comparing high- and low- to- 
moderate- intensity endurance training within a multimodal 
rehabilitation program after treatment also reported no dif-
ferences in CRF.40 However, both of those studies evaluated 
shorter interventions after treatment and are not directly com-
parable to our study.
Additional BCS did not improve CRF or other health out-
comes. This may be because all groups were provided with 
some aspects of BCS, such as supervised training, social 
support, graded tasks, and feedback. These methods have 
previously been associated with higher exercise adherence 
in cancer populations.19,20 This element of the study design 
was a balance between enhancing adherence to the interven-
tion protocol and evaluating the contribution of additional 
BCS. One other plausible explanation for the lack of effect 
of additional BCS on CRF is that participants were relatively 
healthy and well- motivated. It is possible that a broader, more 
heterogeneous clinical population would benefit from such 
support. Further, long- term effects of BCS on adherence and 
CRF need to be examined.
Adherence to the resistance training was within range of 
other exercise interventions including patients undergoing 
curative cancer treatment,41,42 and exercise volume did not 
differ between groups. However, the adherence to the high- 
intensity endurance training was lower than previously re-
ported in studies with similar populations17,43 and lower than 
adherence in the low- to- moderate- intensity groups. One rea-
son for the lower levels in the present study could be that the 
endurance training was home- based. This decision made as 
we, after conducting a feasibility study and receiving input 
from oncology clinicians and patient representatives, deemed 
it would be too demanding for our participants to exercise 
at the gym four times per week. To facilitate adherence to 
the endurance training, all participants had a familiarization 
period of four weeks and the average number of performed 
resistance and endurance sessions reached levels that could 
be expected to make a difference, particularly for participants 
with low fitness levels from start.
Another explanation for the lower adherence to high- 
intensity endurance training compared to other studies could 
be that we used a stringent method for calculating adherence, 
including drop- outs from the intervention and taking both 
intensity and time into account, rather than reporting atten-
dance only. Detailed analysis of adherence according to FITT 
principles in the present study has been reported in a separate 
publication within the research group,44 demonstrating that 
once the participants had made it to the gym, they adhered to 
the prescribed resistance training program to a large extent.
Post- intervention muscle strength was higher in the high- 
intensity exercise group, which is in line with literature in-
dicating that higher loads increase maximal strength more, 
even after controlling for exercise volume.45 Although signif-
icant, the small between- group difference in cardiorespira-
tory fitness is consistent with the idea that not only intensity, 
but also frequency, duration and volume are important ex-
ercise variables for cardiorespiratory fitness during cancer 
treatment.46
Other secondary outcomes did not differ between groups. 
Thus, while it is well- known that exercise during cancer treat-
ment is beneficial compared to usual care for a number of 
health outcomes,47 the results of our second- generation study 
indicate that patients can exercise at either high- or low- to- 
moderate- intensity without missing out on improvement of 
several prevalent side effects.
Although only 29% of the approached patients consented 
to participate, the aim of this study was to compare high- vs 
low- to- moderate- intensity exercise for CRF. As such, inter-
nal validity was prioritized over external validity (general-
izability). Our sample consisted of relatively healthy and 
motivated individuals; mainly well- educated women treated 
for breast cancer. Moreover, individuals included in the main 
analysis had a slightly higher cardiorespiratory fitness and 
health- related quality of life than those who dropped out after 
randomization. However, baseline levels of these factors did 
not differ between randomization groups for those included 
in the analysis. Participants varied in age, current exercise 
levels, and perceived importance of exercise, and it is un-
likely that biological mechanisms related to exercise intensity 
differ in our sample compared with the broader population. 
However, we cannot claim that the results can be generalized 
to the total population of patients with curatively intended 
treatment for breast, prostate, or colorectal cancer, due to the 
different characteristics in the sample and the small propor-
tions of patients with prostate and colorectal cancer.
4.1 | Strengths and limitations
A clear protocol and competent, trained coaches helped en-
sure that the intervention was delivered consistently across 
the different centers and the participants were closely 
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monitored and given frequent face- to- face feedback regard-
ing intensity. Objective measures were used to assess physi-
cal activity as well as maximal testing of cardiorespiratory 
fitness and muscle strength. Supplementary complete cases 
analysis showed largely similar results as the main analysis, 
suggesting that missing data were not differential. However, 
difference between the intention- to- treat and the complete 
case analysis for VO2max suggests that missing data for this 
analysis may be differential.
The study was not powered to draw conclusions about the 
effects of exercise intensity on CRF for specific diagnosis 
groups. However, diagnosis- specific results for breast cancer 
and colorectal cancer were of the same magnitude and direc-
tion as the main results. These findings can be meta- analyzed 
with other studies to inform research on diagnosis- specific 
effects. Blinding coaches and participants to the intervention 
were not feasible. However, there was not strong a- priori in-
formation about which intensity would be better for CRF, so 
this is unlikely to introduce serious bias. Since we did not 
have full control of the home- based endurance training, bias 
may have been introduced if there was differential report-
ing between groups. However, this was limited by providing 
participants with a heart rate monitor to objectively measure 
intensity and duration of home- based training, rather than 
relying on self- report. Furthermore, adherence to the endur-
ance training differed between groups indicating that we did 
not have full control of exercise volume for this intervention 
component.
5 |  CONCLUSIONS
For CRF, we found no clinically important difference be-
tween participants randomized to high- vs low- to- moderate- 
intensity exercise. Patients undergoing (neo- )adjuvant 
treatment for breast, prostate, or colorectal cancer can there-
fore be advised to exercise at either intensity, according to 
their own preferences. There were few and minor adverse 
events during the intervention, indicating that exercise is 
safe, even at high intensity, for these patient groups. In a 
motivated and relatively healthy sample, additional BCS is 
not likely to influence CRF. Future studies are needed to 
evaluate such support in broader clinical populations.
6 |  PERSPECTIVE
It is well established that exercise during and after cancer 
treatment improves CRF7 and international guidelines rec-
ommend cancer survivors to stay active and perform en-
durance and/or resistance training 2- 3 times per week.13 
However, the importance of exercise intensity for CRF is 
unclear. The present study found that participants undergoing 
(neo- )adjuvant cancer treatment exercising at high intensity 
for 6  months demonstrated lower physical fatigue at post- 
intervention, compared to participants exercising at low- to- 
moderate intensity. However, the difference between groups 
was below the threshold for clinical importance. There was 
no effect of behavior change support (goal- setting, planning 
and self- monitoring of exercise) on fatigue. The 6- month 
intervention, including resistance and endurance training, 
caused few minor adverse events, indicating that exercise 
is safe even at high intensity and can be recommended to 
these patient groups. The important message to clinicians is 
that patients undergoing (neo- )adjuvant treatment for breast, 
prostate, or colorectal cancer can be advised that it is safe 
to exercise at either high- or low- to- moderate intensity, ac-
cording to their own preferences. Behavior change support 
in terms of goal- setting, planning, and self- monitoring of ex-
ercise may be unnecessary if patients are relatively healthy, 
motivated for exercise, and participate in supervised, well- 
controlled interventions.
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